ZeeCRO Sells Bioanalytical Division

Tuesday, December 29, 2009 07:42 AM

Cary, N.C.-based contract research organization (CRO) ZeeCRO, formerly AAIPharma Services, sold its bioanalytical division to Kansas Venture Capital, Inc., (KVCI) for an undisclosed sum. KCVI plans to grow the bioanalytical business, which is now a new company, KCAS, Inc.

ZeeCRO streamlined operations to focus on its CRO business in October by selling off its pharmaceutical development services business. As part of that sale, the company lost the rights to the AAIPharma name.  According to ZeeCRO’s web site, the CRO continues to offer early- and late-stage development services to global customers. 

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs